Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/panobinostat-as-pan-deacetylase-inhibitor-for-the-treatment-of-uC9e0kn6ab
References (126)
-
J. Ungerstedt, Y. Sowa, Weisheng Xu, Y. Shao, Milos Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, PA Marks (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Proceedings of the National Academy of Sciences of the United States of America, 102 3
-
(Stewart BW, Wild CP. World cancer report 2014. In: World Health Organization. 2014. Chapter 5.7 (ISBN 92-832-0429-8).)
Stewart BW, Wild CP. World cancer report 2014. In: World Health Organization. 2014. Chapter 5.7 (ISBN 92-832-0429-8).Stewart BW, Wild CP. World cancer report 2014. In: World Health Organization. 2014. Chapter 5.7 (ISBN 92-832-0429-8)., Stewart BW, Wild CP. World cancer report 2014. In: World Health Organization. 2014. Chapter 5.7 (ISBN 92-832-0429-8).
-
H. Prince, D. George, A. Patnaik, M. Mita, M. Dugan, D. Butterfoss, E. Masson, K. Culver, H. Burris, J. Beck (2007)
Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphomaJournal of Clinical Oncology, 25
-
Jessica Bolden, M. Peart, R. Johnstone (2006)
Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 5
-
S. Deleu, E. Menu, E. Valckenborgh, B. Camp, J. Fraczek, I. broek, Vera Rogiers, K. Vanderkerken (2009)
Histone deacetylase inhibitors in multiple myelomaHematology Reviews, 1
-
T. Moriyama, K. Ohuchida, K. Mizumoto, Jun Yu, N. Sato, T. Nabae, S. Takahata, H. Toma, E. Nagai, Masao Tanaka (2009)
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistanceMolecular Cancer Therapeutics, 8
-
J. Ryu, Woojin Lee, K. Lee, Jin-Hyeok Hwang, Yong-Tae Kim, Y. Yoon, C. Kim (2006)
SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.Cancer letters, 237 1
-
P. García-Morales, Angeles Gómez-Martínez, A. Carrato, I. Martínez-Lacaci, V. Barberá, J. Soto, E. Carrasco-Garcia, M. Menéndez-Gutiérrez, M. Castro-Galache, J. Ferragut, M. Saceda (2005)
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell linesMolecular Cancer Therapeutics, 4
-
(2014)
FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma -
O. Mehdi, S. Françoise, C. Sofia, G. Urs, Z. Kevin, S. Bernard, S. Igor, C. Anabela, Lombardo Dominique, M. Eric, O. Ali (2012)
HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 12 2
-
Muktheshwar Gandesiri, Saritha Chakilam, Jeļena Ivanovska, Natalya Benderska, M. Ocker, P. Fazio, M. Feoktistova, H. Gali-Muhtasib, M. Rave-Fränk, O. Prante, H. Christiansen, M. Leverkus, A. Hartmann, R. Schneider-Stock (2012)
DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditionsApoptosis, 17
-
T. Kumagai, N. Wakimoto, D. Yin, S. Gery, N. Kawamata, N. Takai, N. Komatsu, A. Chumakov, Y. Imai, H. Koeffler (2007)
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cellsInternational Journal of Cancer, 121
-
Guan Wang, Guan Wang, Xiaojia Niu, Wenbo Zhang, J. Caldwell, Holly Edwards, Wei Chen, J. Taub, J. Taub, Lijing Zhao, Y. Ge, Y. Ge (2015)
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Cancer letters, 356 2 Pt B
-
Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang, Kristina Thiel, K. Leslie (2011)
Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-TreatmentPLoS ONE, 6
-
C. Dell'Aversana, I. Lepore, L. Altucci (2012)
HDAC modulation and cell death in the clinic.Experimental cell research, 318 11
-
L. Ellis, H. Hammers, R. Pili (2009)
Targeting tumor angiogenesis with histone deacetylase inhibitors.Cancer letters, 280 2
-
D. Birnbaum, E. Mamessier, D. Birnbaum (2012)
The emerging role of the TGFβ tumor suppressor pathway in pancreatic cancerCell Cycle, 11
-
H. Rikiishi (2010)
Possible Role of Autophagy in the Treatment of Pancreatic Cancer with Histone Deacetylase InhibitorsCancers, 2
-
피터 아타드자, 리키 존스톤, 헨리 프린스, 마크 비쉬톤, 시몬 해리슨 (2011)
Combination of hdac inhibitors with thrombocytopenia drugs -
R. Feld, M. Woo, N. Leighl, F. Shepherd, J. Beck, Lihui Zhao, L. Gazi, T. Hengelage, M. Porro, Asha Nayak (2013)
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancerCancer Chemotherapy and Pharmacology, 72
-
B. Wang, Xin-bao Wang, Li-yu Chen, Ling Huang, Rui Dong (2013)
Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis.Biochemical and biophysical research communications, 437 1
-
(2015)
FDA approves Farydak for treatment of multiple myeloma -
(Farrell JJ, Fernandez del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gasroenterology. 2013;144(6):1303–15.)
Farrell JJ, Fernandez del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gasroenterology. 2013;144(6):1303–15.Farrell JJ, Fernandez del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gasroenterology. 2013;144(6):1303–15., Farrell JJ, Fernandez del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gasroenterology. 2013;144(6):1303–15.
-
M. Donadelli, C. Costanzo, S. Beghelli, M. Scupoli, M. Dandrea, A. Bonora, P. Piacentini, A. Budillon, M. Caraglia, A. Scarpa, M. Palmieri (2007)
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.Biochimica et biophysica acta, 1773 7
-
M. Iwatsuki, K. Mimori, T. Yokobori, Hideshi Ishi, T. Beppu, S. Nakamori, H. Baba, M. Mori (2010)
Epithelial–mesenchymal transition in cancer development and its clinical significanceCancer Science, 101
-
Arthur Edwards, Jiannong Li, P. Atadja, K. Bhalla, E. Haura (2007)
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cellsMolecular Cancer Therapeutics, 6
-
V. Sung, Normand Richard, H. Brady, A. Maier, G. Kelter, C. Heise (2011)
Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cellsCancer Science, 102
-
C. Caldas, S. Hahn, L. Costa, M. Redston, M. Schutte, A. Seymour, Craig Weinstein, R. Hruban, C. Yeo, S. Kern (1994)
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinomaNature Genetics, 8
-
Thiruvengadam Arumugam, V. Ramachandran, K. Fournier, Huamin Wang, L. Marquis, J. Abbruzzese, G. Gallick, C. Logsdon, D. McConkey, W. Choi (2009)
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.Cancer research, 69 14
-
(2009)
Histone deacetylase inhibitors in multiple myelomaMyeloma therapy
-
B. Stewart, P. Kleihues (2003)
World Cancer Report -
Yiqi Du, Ming-hao Liu, Jun Gao, Zhaoshen Li (2013)
Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation.Cancer biotherapy & radiopharmaceuticals, 28 5
-
Brahma Singh, Guanghua Zhang, Y. Hwa, Jinping Li, S. Dowdy, Shi-Wen Jiang (2010)
Nonhistone protein acetylation as cancer therapy targetsExpert Review of Anticancer Therapy, 10
-
A. Aghdassi, M. Sendler, A. Guenther, J. Mayerle, C.-O. Behn, C. Heidecke, H. Friess, M. Büchler, M. Evert, M. Lerch, F. Weiss (2011)
Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancerGut, 61
-
T Hideshima (2009)
Myeloma therapy -
Jiahao Jiang, Chen Liu, He Cheng, Yu Lu, Yi Qin, Yong-feng Xu, Jin Xu, J. Long, Liang Liu, Q. Ni, Xianjun Yu (2015)
Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?Biochimica et biophysica acta, 1855 1
-
Sachi Morita, S. Oizumi, H. Minami, K. Kitagawa, Y. Komatsu, Y. Fujiwara, M. Inada, S. Yuki, N. Kiyota, A. Mitsuma, M. Sawaki, H. Tanii, J. Kimura, Y. Ando (2012)
Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumorsInvestigational New Drugs, 30
-
M. Truty, G. Lomberk, M. Fernandez-Zapico, R. Urrutia (2009)
Silencing of the Transforming Growth Factor-β (TGFβ) Receptor II by Krüppel-like Factor 14 Underscores the Importance of a Negative Feedback Mechanism in TGFβ Signaling*S⃞The Journal of Biological Chemistry, 284
-
(Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies (abstract no 958). Blood. 2008;112.)
Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies (abstract no 958). Blood. 2008;112.Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies (abstract no 958). Blood. 2008;112., Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies (abstract no 958). Blood. 2008;112.
-
(1954)
THE WORLD HEALTH ORGANIZATIONMedical Journal of Australia, 2
-
Guan Wang, Jing He, J. Taub, Yingjie Guo, Y. Ge (2012)
Abstract 1830: Both class I and class II histone deacetylases are required for proliferation and survival of human pancreatic cancer cellsCancer Research, 72
-
(2016)
Oncol Ther -
Accessed 16 -
Y. Delpu, N. Hanoun, H. Lulka, F. Sicard, J. Selves, L. Buscail, J. Torrisani, P. Cordelier (2011)
Genetic and Epigenetic Alterations in Pancreatic CarcinogenesisCurrent Genomics, 12
-
Guan Wang, Jing He, Jianyun Zhao, Wenting Yun, C. Xie, J. Taub, A. Azmi, R. Mohammad, Yan Dong, W. Kong, Yingjie Guo, Y. Ge (2012)
Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic CancerPLoS ONE, 7
-
M. Prystowsky, Katherine Feeney, N. Kawachi, C. Montagna, Michelle Willmott, Christopher Wasson, M. Antkowiak, O. Loudig, Joanna Parish (2013)
Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic DefectsScientific Reports, 3
-
(US FDA. FDA approves Farydak for treatment of multiple myeloma. Feb 23, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm. Accessed 6 Sept 2015.)
US FDA. FDA approves Farydak for treatment of multiple myeloma. Feb 23, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm. Accessed 6 Sept 2015.US FDA. FDA approves Farydak for treatment of multiple myeloma. Feb 23, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm. Accessed 6 Sept 2015., US FDA. FDA approves Farydak for treatment of multiple myeloma. Feb 23, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm. Accessed 6 Sept 2015.
-
Petra Fritsche, B. Seidler, S. Schüler, A. Schnieke, M. Göttlicher, RolandM. Schmid, D. Saur, G. Schneider (2009)
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXAGut, 58
-
M. Ouaïssi, I. Sielezneff, R. Silvestre, B. Sastre, J. Bernard, J. Lafontaine, M. Payan, L. Dahan, N. Pirró, J. Seitz, E. Mas, D. Lombardo, A. Ouaissi (2008)
High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the PancreasAnnals of Surgical Oncology, 15
-
(US FDA. FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma. July 3, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm; Accessed 6 Sept 2015.)
US FDA. FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma. July 3, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm; Accessed 6 Sept 2015.US FDA. FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma. July 3, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm; Accessed 6 Sept 2015., US FDA. FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma. July 3, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm; Accessed 6 Sept 2015.
-
M. Haefner, T. Bluethner, M. Niederhagen, C. Moebius, C. Wittekind, J. Mossner, K. Caca, M. Wiedmann (2008)
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.World journal of gastroenterology, 14 23
-
Mary Dillhoff, James Liu, W. Frankel, C. Croce, M. Bloomston (2008)
MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of SurvivalJournal of Gastrointestinal Surgery, 12
-
(Foundation for Promotion of Cancer Research. Cancer statistics in Japan-2011. http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed 20 Oct 2012.)
Foundation for Promotion of Cancer Research. Cancer statistics in Japan-2011. http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed 20 Oct 2012.Foundation for Promotion of Cancer Research. Cancer statistics in Japan-2011. http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed 20 Oct 2012., Foundation for Promotion of Cancer Research. Cancer statistics in Japan-2011. http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed 20 Oct 2012.
-
W. Chien, D. Lee, Yun Zheng, P. Wuensche, R. Alvarez, Ding Wen, A. Aribi, Su Thean, N. Doan, J. Said, H. Koeffler (2014)
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivoMolecular Carcinogenesis, 53
-
J. Farrell, C. Castillo (2013)
Pancreatic cystic neoplasms: management and unanswered questions.Gastroenterology, 144 6
-
Sandra Baumgart, E. Glesel, Garima Singh, Nai-Ming Chen, K. Reutlinger, Jinsan Zhang, D. Billadeau, M. Fernandez-Zapico, T. Gress, Shiv Singh, V. Ellenrieder (2012)
Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer.Gastroenterology, 142 2
-
H. Rajak, A. Singh, K. Raghuwanshi, R. Kumar, P. Dewangan, R. Veerasamy, P. Sharma, A. Dixit, P. Mishra (2013)
A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.Current medicinal chemistry, 21 23
-
(Atadja PW, Bishton MJ, Harrison SJ, et al. Combination of HDAC inhibitors with thrombocytopenia drugs. 2012;(WO 2012030886 A1).)
Atadja PW, Bishton MJ, Harrison SJ, et al. Combination of HDAC inhibitors with thrombocytopenia drugs. 2012;(WO 2012030886 A1).Atadja PW, Bishton MJ, Harrison SJ, et al. Combination of HDAC inhibitors with thrombocytopenia drugs. 2012;(WO 2012030886 A1)., Atadja PW, Bishton MJ, Harrison SJ, et al. Combination of HDAC inhibitors with thrombocytopenia drugs. 2012;(WO 2012030886 A1).
-
(2009)
Histone deacetylase inhibitors current status and overview of recent clinical trialsDrugs., 69
-
Johanna Ungerstedt, Yatao Du, Huihui Zhang, Deepika Nair, Arne Holmgren (2012)
In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).Free radical biology & medicine, 53 11
-
P. Atadja (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.Cancer letters, 280 2
-
F. Giles, T. Fischer, J. Cortes, G. Garcia-Manero, J. Beck, F. Ravandi, E. Masson, Patricia Rae, G. Laird, Sunil Sharma, H. Kantarjian, M. Dugan, M. Albitar, K. Bhalla (2006)
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic MalignanciesClinical Cancer Research, 12
-
S. Subramanian, S. Bates, J. Wright, I. Espinoza‐Delgado, R. Piekarz (2010)
Clinical Toxicities of Histone Deacetylase InhibitorsPharmaceuticals, 3
-
S. Clive, M. Woo, M. Stewart, T. Nydam, S. Hirawat, M. Kagan (2009)
Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
Zacharoula Konsoula, H. Cao, A. Velena, M. Jung (2009)
Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitorsMolecular Cancer Therapeutics, 8
-
C. Giver, D. Jaye, E. Waller, J. Kaufman, S. Lonial (2011)
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytesLeukemia, 25
-
Harald Maier, T. Wirth, H. Beug (2010)
Epithelial-Mesenchymal Transition in Pancreatic CarcinomaCancers, 2
-
Z. Qiao, Suping Ren, Weijing Li, Xuanlin Wang, Min He, Yingjie Guo, Liwei Sun, Yuezhong He, Y. Ge, Qun Yu (2013)
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.Biochemical and biophysical research communications, 434 1
-
Karly Garnock-jones (2015)
Panobinostat: First Global ApprovalDrugs, 75
-
F. Emura, D. Saito, T. Kakizoe, M. Blaser (2006)
Infection, cancer and prevention: report of the 19th International Symposium of the Foundation for Promotion of Cancer Research.Japanese journal of clinical oncology, 36 11
-
(von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137(1):361–71, 371.e1–5.)
von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137(1):361–71, 371.e1–5.von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137(1):361–71, 371.e1–5., von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137(1):361–71, 371.e1–5.
-
Johannes Burstin, S. Eser, M. Paul, B. Seidler, M. Brandl, M. Messer, A. Werder, A. Schmidt, J. Mages, P. Pagel, A. Schnieke, R. Schmid, G. Schneider, D. Saur (2009)
E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.Gastroenterology, 137 1
-
Yoko Katsuno, Samy Lamouille, R. Derynck (2013)
TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progressionCurrent Opinion in Oncology, 25
-
A. Fukutomi, K. Hatake, K. Matsui, S. Sakajiri, T. Hirashima, H. Tanii, Ken Kobayashi, N. Yamamoto (2012)
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumorsInvestigational New Drugs, 30
-
(The medical subject Headings indexing system refers to “islet cell carcinoma”, which is subdivided into gastrinoma, glucagonoma, somatostatinoma and VIPoma. In: MeSH tree at pancreatic neoplasms. 2014. [C04: 588: 322.475]. Accessed 16 Oct 2014.)
The medical subject Headings indexing system refers to “islet cell carcinoma”, which is subdivided into gastrinoma, glucagonoma, somatostatinoma and VIPoma. In: MeSH tree at pancreatic neoplasms. 2014. [C04: 588: 322.475]. Accessed 16 Oct 2014.The medical subject Headings indexing system refers to “islet cell carcinoma”, which is subdivided into gastrinoma, glucagonoma, somatostatinoma and VIPoma. In: MeSH tree at pancreatic neoplasms. 2014. [C04: 588: 322.475]. Accessed 16 Oct 2014., The medical subject Headings indexing system refers to “islet cell carcinoma”, which is subdivided into gastrinoma, glucagonoma, somatostatinoma and VIPoma. In: MeSH tree at pancreatic neoplasms. 2014. [C04: 588: 322.475]. Accessed 16 Oct 2014.
-
Kai Cao, G. Wang, Wenzhao Li, Liying Zhang, Liying Zhang, Ruoxiang Wang, Y. Huang, L. Du, J. Jiang, C. Wu, X. He, Arthur Roberts, Fang Li, Arnold Rabson, Ying Wang, Yufang Shi, Yufang Shi, Yufang Shi (2015)
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunityOncogene, 34
-
(Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin’s lymphoma (abstract no 3500). J Clin Oncol. 2007;25(18suppl).)
Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin’s lymphoma (abstract no 3500). J Clin Oncol. 2007;25(18suppl).Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin’s lymphoma (abstract no 3500). J Clin Oncol. 2007;25(18suppl)., Prince HM, George D, Patnaik A, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin’s lymphoma (abstract no 3500). J Clin Oncol. 2007;25(18suppl).
-
B. Gryder, Q. Sodji, A. Oyelere (2012)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Future medicinal chemistry, 4 4
-
(2014)
The medical subject Headings indexing system refers to ''islet cell carcinoma'', which is subdivided into gastrinoma, glucagonoma, somatostatinoma and VIPoma -
PA Marks, W-S Xu (2009)
Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 107
-
G. Shapiro, R. Frank, U. Dandamudi, T. Hengelage, Lily Zhao, L. Gazi, M. Porro, M. Woo, L. Lewis (2012)
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancerCancer Chemotherapy and Pharmacology, 69
-
O. Ottmann, A. Spencer, H. Prince, K. Bhalla, T. Fischer, Angela Liu, K. Parker, M. Jalaluddin, G. Laird, M. Woo, Jeffrey Scott, Daniel DeAngelo (2008)
Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.Blood, 112
-
T. Kitamura, D. Inoue (2012)
HDACI-induced thrombocytopenia is caused by its unexpected target.Experimental hematology, 40 9
-
J. Kauh, S. Fan, Mingjing Xia, P. Yue, Lily Yang, F. Khuri, Shi-Yong Sun (2010)
c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589PLoS ONE, 5
-
B. Schuettengruber, D. Chourrout, M. Vervoort, Benjamin Leblanc, Giacomo Cavalli (2007)
Genome Regulation by Polycomb and Trithorax ProteinsCell, 128
-
N. Mitsiades, C. Mitsiades, P. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. Munshi, T. Hideshima, V. Richon, P. Marks, K. Anderson (2003)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood, 101 10
-
M. Bishton, H. Prince, S. Harrison, B. Martin, J. Emma, C. James, K. Henley, B. Kile, R. Johnstone (2011)
Abstract 2613: Histone deacetylase inhibitor induced thrombocytopenia occurs due to inhibition platelet shedding by megakaryocytes, via increased phosporylation of myosin light chainCancer Research, 71
-
J. Bodo, Xiaoxian Zhao, Arishya Sharma, B. Hill, C. Portell, B. Lannutti, A. Almasan, E. Hsi (2013)
The phosphatidylinositol 3‐kinases (PI3K) inhibitor GS‐1101 synergistically potentiates histone deacetylase inhibitor‐induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal‐regulated kinase pathwaysBritish Journal of Haematology, 163
-
M. Slingerland, D. Hess, S. Clive, Sunil Sharma, Per Sandstrom, N. Loman, M. Porro, S. Mu, Edward Waldron, Sue-zette Valera, H. Gelderblom (2014)
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic functionCancer Chemotherapy and Pharmacology, 74
-
M. Bishton, E. Gardiner, S. Harrison, H. Prince, R. Johnstone (2013)
Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.Thrombosis research, 131 6
-
W. Shao, J. Growney, Y. Feng (2008)
Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models -
D. Qian, Y. Kato, S. Shabbeer, Yongfeng Wei, H. Verheul, Brenda Salumbides, Tolib Sanni, P. Atadja, R. Pili (2006)
Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589Clinical Cancer Research, 12
-
F. Natoni, L. Diolordi, C. Santoni, M. Montani (2005)
Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways.Biochimica et biophysica acta, 1745 3
-
P. Hamberg, M. Woo, Lin-Chi Chen, J. Verweij, M. Porro, Lily Zhao, Wenkui Li, D. Biessen, Sunil Sharma, T. Hengelage, M. Jonge (2011)
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorCancer Chemotherapy and Pharmacology, 68
-
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto, K. Bhalla (2005)
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90Journal of Biological Chemistry, 280
-
Sreedhar Venkannagari, W. Fiskus, K. Peth, P. Atadja, M. Hidalgo, A. Maitra, K. Bhalla (2012)
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancerOncotarget, 3
-
G. Schneider, O. Krämer, RolandM. Schmid, D. Saur (2011)
Acetylation as a Transcriptional Control Mechanism—HDACs and HATs in Pancreatic Ductal AdenocarcinomaJournal of Gastrointestinal Cancer, 42
-
F. Roy, Geert Berx (2008)
The cell-cell adhesion molecule E-cadherinCellular and Molecular Life Sciences, 65
-
M. Goggins, M. Shekher, Kenan Turnacioglu, C. Yeo, R. Hruban, S. Kern (1998)
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.Cancer research, 58 23
-
R. Reddy, Wen‐Shuz Yeow, A. Chua, D. Nguyen, A. Baras, M. Ziauddin, S. Shamimi-Noori, J. Maxhimer, D. Schrump, D. Nguyen (2006)
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascadeApoptosis, 12
-
T. Rasmussen, O. Søgaard, C. Brinkmann, F. Wightman, S. Lewin, J. Melchjorsen, C. Dinarello, L. Østergaard, M. Tolstrup (2013)
Comparison of HDAC inhibitors in clinical developmentHuman Vaccines & Immunotherapeutics, 9
-
A. Arlt, S. Müerköster, H. Schäfer (2013)
Targeting apoptosis pathways in pancreatic cancer.Cancer letters, 332 2
-
Shujie Zhao, K. Venkatasubbarao, Senlin Li, J. Freeman (2003)
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.Cancer research, 63 10
-
Suzanne Jones, J. Bendell, J. Infante, D. Spigel, Dana Thompson, D. Yardley, F. Greco, P. Murphy, H. Burris (2011)
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.Clinical advances in hematology & oncology : H&O, 9 3
-
Hyun‐Jung Kim, S. Bae (2011)
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.American journal of translational research, 3 2
-
(2011)
Apoptosis and the target genes of microRNA-21Chin J Cancer., 30
-
P. Moore, S. Barbi, M. Donadelli, C. Costanzo, C. Bassi, M. Palmieri, A. Scarpa (2004)
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.Biochimica et biophysica acta, 1693 3
-
A. Newbold, R. Lindemann, L. Cluse, K. Whitecross, A. Dear, R. Johnstone (2008)
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinMolecular Cancer Therapeutics, 7
-
(Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology. 2012;142(2):388–98.e1–7.)
Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology. 2012;142(2):388–98.e1–7.Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology. 2012;142(2):388–98.e1–7., Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology. 2012;142(2):388–98.e1–7.
-
Y. Zou, G. Howell, L. Humphrey, Jing Wang, M. Brattain (2013)
Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)PLoS ONE, 8
-
Shusheng Wang, X. Li, M. Parra, E. Verdin, R. Bassel-Duby, E. Olson (2008)
Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7Proceedings of the National Academy of Sciences, 105
-
Hengbing Wang, Q. Cao, A. Dudek (2012)
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.Anticancer research, 32 3
-
D. Lisiero, H. Soto, R. Everson, L. Liau, R. Prins (2014)
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cellsJournal for Immunotherapy of Cancer, 2
-
(Bishton MJ, Prince HM, Harrison SJ, et al. Histone deacetylase inhibitor induced thrombocytopenia occurs due to inhibition platelet shedding by megakaryocytes, via increased phosporylation of myosin light chain (abstract 2613). Cancer Res. 2011;71.)
Bishton MJ, Prince HM, Harrison SJ, et al. Histone deacetylase inhibitor induced thrombocytopenia occurs due to inhibition platelet shedding by megakaryocytes, via increased phosporylation of myosin light chain (abstract 2613). Cancer Res. 2011;71.Bishton MJ, Prince HM, Harrison SJ, et al. Histone deacetylase inhibitor induced thrombocytopenia occurs due to inhibition platelet shedding by megakaryocytes, via increased phosporylation of myosin light chain (abstract 2613). Cancer Res. 2011;71., Bishton MJ, Prince HM, Harrison SJ, et al. Histone deacetylase inhibitor induced thrombocytopenia occurs due to inhibition platelet shedding by megakaryocytes, via increased phosporylation of myosin light chain (abstract 2613). Cancer Res. 2011;71.
-
Yong Li, Lindsey Buscaglia
Chinese Anti鄄 Cancer a Ssociation -
A. Ougolkov, V. Bilim, D. Billadeau (2008)
Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2Clinical Cancer Research, 14
-
S. Fulda (2008)
Modulation of TRAIL-induced apoptosis by HDAC inhibitors.Current cancer drug targets, 8 2
-
Tao Liu, S. Kuljaca, A. Tee, G. Marshall (2006)
Histone deacetylase inhibitors: multifunctional anticancer agents.Cancer treatment reviews, 32 3
-
(Shao W, Growney J, Feng Y, et al. Potent anticancer activity of a pandeacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models (abstract no 735). Cancer Res. 2008;68.)
Shao W, Growney J, Feng Y, et al. Potent anticancer activity of a pandeacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models (abstract no 735). Cancer Res. 2008;68.Shao W, Growney J, Feng Y, et al. Potent anticancer activity of a pandeacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models (abstract no 735). Cancer Res. 2008;68., Shao W, Growney J, Feng Y, et al. Potent anticancer activity of a pandeacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models (abstract no 735). Cancer Res. 2008;68.
-
(Clive S, Woo MM, Stewart M, et al. Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat (abstract no. 2549). J Clin Oncol. 2009;27(15 Suppl).)
Clive S, Woo MM, Stewart M, et al. Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat (abstract no. 2549). J Clin Oncol. 2009;27(15 Suppl).Clive S, Woo MM, Stewart M, et al. Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat (abstract no. 2549). J Clin Oncol. 2009;27(15 Suppl)., Clive S, Woo MM, Stewart M, et al. Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat (abstract no. 2549). J Clin Oncol. 2009;27(15 Suppl).
-
Sunil Sharma, P. Witteveen, M. Lolkema, D. Hess, H. Gelderblom, S. Hussain, M. Porro, Edward Waldron, Sue-zette Valera, S. Mu (2014)
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal functionCancer Chemotherapy and Pharmacology, 75
-
Chunrong Yu, B. Friday, Jinping Lai, A. McCollum, P. Atadja, L. Roberts, A. Adjei (2007)
Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species GenerationClinical Cancer Research, 13
-
S. Raimondi, P. Maisonneuve, A. Lowenfels (2009)
Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology &Hepatology, 6
-
S. Schüler, Petra Fritsche, Sandra Diersch, A. Arlt, R. Schmid, D. Saur, G. Schneider (2010)
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cellsMolecular Cancer, 9
-
M. Ocker, R. Schneider-Stock (2007)
Histone deacetylase inhibitors: signalling towards p21cip1/waf1.The international journal of biochemistry & cell biology, 39 7-8
-
Lei Zhang, D. Lebwohl, E. Masson, G. Laird, Michael Cooper, H. Prince (2008)
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 2
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by The Author(s)
- Subject
- Medicine & Public Health; Internal Medicine
- ISSN
- 2366-1070
- eISSN
- 2366-1089
- DOI
- 10.1007/s40487-016-0023-1
- Publisher site
- See Article on Publisher Site
Abstract
The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac®, LBH589) was developed by Novartis Pharmaceuticals and has been recently approved by the US Food and Drug Administraion (FDA) as a drug to treat multiple myeloma. It is under clinical investigation for a range of haematological and solid tumors worldwide in both oral and intravenous formulations. Panobinostat inhibits tumor cell growth by interacting with acetylation of histones and non-histone proteins as well as various apoptotic, autophagy-mediated targets and various tumorogenesis pathways involved in development of tumors. The optimal combination regimen for pancreatic cancer remains to be fully elucidated with various combination regimens, and should be investigated in clinical trials. This article summarizes the current preclinical and clinical status of panobinostat in pancreatic cancer. Preclinical data suggests that panobinostat has potential inhibitory activity in pancreatic cancer cells by targeting various pathways and factors involved in the development of cancer. Herein, we reviewed the status of mono and combination therapy and the rationale behind the combination therapy undergoing trials, as well as possible future prospective use in the treatment of pancreatic cancer.
Journal
Oncology and Therapy – Springer Journals
Published: Jun 10, 2016